Overall survival by 3 groups. (A) Total population, (B) patients treated with dasatinib, and (C) patients treated with nilotinib. MCyR+CHRc indicates a MCyR plus a concomitant CHR; MCyR+no conc. CHR indicates a MCyR with no concomitant CHR. Censored cases are shown with vertical tick marks. P values were calculated by the log-rank test for heterogeneity.